01—Abstract
Summary
Summary of the 10-K filed February 20, 2009. Cited figures are marked; the original filing is the authoritative source.
Stryker Corporation's 2008 10-K filing reveals a robust year of growth, with net sales reaching $6.7 billiona, a 12% increase over 2007.
This growth was driven by strong performance across both its Orthopaedic Implants and MedSurg Equipment segments, with international sales showing a notable 13% increase. Despite a challenging economic climate, particularly impacting hospital capital budgets in the latter half of the year, Stryker demonstrated resilience, with significant sales increases in key areas like knee implants (14%), trauma implants (18%), and patient handling equipment (18%). The company also reported a 16% increase in net earnings from continuing operations to $1.15 billionb.
Management highlighted its focus on innovation and new product introductions, such as the Tritanium Primary Hip System and the S3 Med/Surg Hospital Bed, as critical to its growth strategy. While the company faced some regulatory challenges, including warning letters related to quality systems, it actively cooperated with authorities to address these issues. Stryker also continued its share repurchase program, underscoring its commitment to returning value to shareholders.
02—Key points
Key Highlights
- Achieved 12% net sales growth, reaching $6.7 billion in 2008, driven by strong performance in both Orthopaedic Implants and MedSurg Equipment segments.
- Reported a 16% increase in net earnings from continuing operations to $1.15 billion, with diluted EPS of $2.78.
- Demonstrated significant international sales growth of 13%, contributing to overall revenue expansion.
- Experienced robust growth in key product categories, including knee implants (14%), trauma implants (18%), and patient handling equipment (18%).
- Continued investment in research and development, totaling $367.8 million, with a focus on new product introductions to drive future growth.
- Maintained a strong financial position with $701.1 million in cash and cash equivalents and substantial operating cash flow ($1.18 billion).
- Successfully navigated the challenging economic environment and addressed regulatory compliance issues, demonstrating operational resilience.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2008, Stryker Corp kept $0.17.
- Revenue$6.72B100.0%
- Cost of revenue−$2.13B31.7%
- Gross profit$4.59B68.3%
- Operating costs−$3.07B45.7%
- Operating income$1.52B22.6%
- Interest, other & tax−$371.2M5.5%
- Net income$1.15B17.1%
Where FY2008 revenue went
$6.72B- SG&A: $2.63B, 39% of revenue
- Cost of revenue: $2.13B, 32% of revenue
- Net income: $1.15B, 17% of revenue
- R&D: $367.8M, 5.5% of revenue
- Other operating costs: $74.9M, 1.1% of revenue
- Interest, other & tax: $371.2M, 5.5% of revenue
Kept 17% as net incomeOther operating costs $74.9M · 1.1%
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2008filed February 20, 2009Financial Statements
FY2008 against FY2007
| Line item | FY2008FY2007 | Change |
|---|---|---|
| Revenue | $6.72B$6.00B | +12.0% |
| Cost of Revenue | $2.13B$1.87B | +14.3% |
| Gross Profit | $4.59B$4.14B | +10.9% |
| R&D Expenses | $367.80M$375.30M | −2.0% |
| SG&A Expenses | $2.63B$2.39B | +9.8% |
| Operating Expenses | $3.07B$2.83B | +8.5% |
| Operating Income | $1.52B$1.31B | +16.2% |
| Interest Expense | $12.70M— | — |
| Net Income | $1.15B$1.02B | +12.8% |
| EPS (Basic) | $2.81$2.48 | +13.3% |
| EPS (Diluted) | $2.78$2.44 | +13.9% |
| Shares Outstanding (Basic) | 408.10M— | — |
| Shares Outstanding (Diluted) | 413.60M— | — |
05—Questions
Frequently Asked Questions
What was Stryker's overall financial performance in 2008?
In 2008, Stryker reported a 12% increase in net sales to $6.7 billion and a 16% increase in net earnings from continuing operations to $1.15 billion. Diluted earnings per share from continuing operations were $2.78. The company saw growth in both its Orthopaedic Implants and MedSurg Equipment segments, with international sales performing particularly well.
How did the economic slowdown affect Stryker's business in 2008?
The general economic slowdown in the United States led to a significant contraction in hospital capital budgets, which depressed demand for certain MedSurg Equipment products. However, the company managed to mitigate some of these impacts through disciplined spending and continued sales growth in other areas.
What are the key product segments for Stryker, and how did they perform?
Stryker operates primarily through two segments: Orthopaedic Implants and MedSurg Equipment. In 2008, Orthopaedic Implants sales grew 11% and MedSurg Equipment sales grew 14%. Specific product lines like knee implants (14% growth) and trauma implants (18% growth) showed particularly strong performance.
Did Stryker face any significant regulatory or legal challenges during 2008?
Yes, Stryker received warning letters from the FDA concerning quality systems at certain manufacturing facilities and was cooperating with investigations by the Department of Justice related to consulting contracts and the promotion of certain products. The company stated it was fully cooperating with all authorities regarding these matters.
06—Continue